Financing channel feed – Endpoints News

Financing channel feed

CF Foundation backs a new round for a biotech upstart out to rival the mighty Vertex

5 years ago

'Dude, you're getting a Dell' — as a new deep-pocket biotech investor

5 years ago

A Third Rock-backed player charts a new course against transcription factors. Do 'switch sites' hold the magic sauce?

5 years ago

With backing from Bayer, a London firm will pitch its 'hospitals at home' concept for decentralized trials

5 years ago

Perceptive Advisors, Xontogeny bring the band back and then some with a $515M second fund sniffing out lead compounds

5 years ago

The growing liquid biopsy field sees a unicorn entrant as Caris pulls in $830M megaround

5 years ago

Alexion co-founder Stephen Squinto is back in the game as CEO, this time for a small gene therapy player

5 years ago

George Golumbeski signs on at a European specialist VC firm with $265M to bet on genetic diseases

5 years ago

The fight against drug-resistant bacteria marches forward as Adaptive Phage earns $40M+ Series B

5 years ago

Months after emerging from stealth, Nuvalent follows up with $135M Series B — backed by some active players on the biotech IPO scene

5 years ago

Ginkgo Bioworks resizes the definition of going big in biotech, raising $2.5B in a record SPAC deal that weighs in with a whopping $15B-plus valuation

5 years ago

RWE upstart maps a new global plan as investors pour in the latest mega-round

5 years ago

Nobel laureate David Baltimore throws his weight behind I/O startup looking to craft off-the-shelf CAR therapies

5 years ago

Samantha Du's Quan Capital, Lilly Asia back China's first big kidney play

5 years ago

The company behind Moderna has a new RNA startup looking to disrupt drugmaking. The goal? 100 new drugs in 10 years

5 years ago

Ex-Harvard professor and serial entrepreneur Omid Farokhzad jumps into the SPAC game with some industry insiders and a certain billionaire scientist

5 years ago

Let’s make that $1B-plus: Abingworth gathers more cash, this time for its late-stage poker game. And we learned that even a biotech nuclear winter has its advantages

5 years ago

Hours before expected debut, Gyroscope postpones its IPO as 2 other biotechs hold the line on their march to Nasdaq

5 years ago

Amid virtual trial craze, Science 37 earns unicorn status and a trip to Nasdaq on the back of SPAC deal

5 years ago

A 'flyover' biotech launches in Texas with four Ron DePinho-founded companies under its belt

5 years ago

Goldman Sachs jumps aboard Bain-backed 503(b) compounding pharmacy with a $275M debt loan to supply hospitals

5 years ago

Jasper and its stem cell conditioning antibody earn a ticket to Nasdaq in latest SPAC reverse merger

5 years ago

The Harvard scientist acting as ATAI's treasure trove launches a new psychedelics firm focused on drug 'analogues'

5 years ago

Dyno's Eric Kelsic fills the tank in his quest for better AAV with a group of big-name supporters on board

5 years ago

First page Previous page 75 76 777879 80 81 Next page Last page